Susana Martinez Diaz1, Naeem Bhojani2, Dean Elterman3, Kevin Zorn2, Steven A Kaplan4, Tobias S Kohler5, Lori B Lerner6, Kevin T McVary7, Matthew P Rutman8, Charles Welliver9, Alexis E Te1, Art Sedrakyan10, Bilal Chughtai11. 1. Department of Urology, Weill Cornell Medicine, 425 East 61st Street, 12th Floor, New York City, NY, 10065, USA. 2. Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montreal, QC, Canada. 3. Division of Urology, University Health Network (UHN), University of Toronto, Toronto, ON, Canada. 4. Department of Urology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. 5. Department of Urology, Mayo Clinic, Rochester, MN, USA. 6. Department of Urology, VA Boston Healthcare System, Boston, MA, USA. 7. Center for Male Health, Loyola University Medical Center, Maywood, IL, USA. 8. Department of Urology, Columbia University, New York, NY, USA. 9. Department of Urology, Albany Medical College, Albany, NY, USA. 10. Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA. 11. Department of Urology, Weill Cornell Medicine, 425 East 61st Street, 12th Floor, New York City, NY, 10065, USA. bic9008@med.cornell.edu.
Abstract
PURPOSE: To create a prospective, multicenter coordinated registry network (CRN) of robust "real world" data for benign prostatic hyperplasia (BPH) that links surgical practices to objective and subjective outcomes of patients who undergo surgery for the improvement in lower urinary tract symptoms (LUTS) secondary to BPH. METHODS: We gathered a group of BPH experts from various institutions to identify the minimum core data elements needed to assess BPH procedures. To achieve consensus on the data elements, we used a Delphi method adaptation, in which a series of surveys were answered by the expert panel individually and anonymously. Survey results were collected and analyzed. Questions for the following round were based on response analysis from the prior survey. This process was repeated until consensus was achieved. RESULTS: Participation rates in the first and second rounds were 100% and 90%, respectively. The expert panel reached consensus on 148 data elements out of the 182 proposed, capturing patient medical and surgical history, procedure, discharge, short- and long-term follow-up, device factors, surgery, and surgeon factors. CONCLUSION: We have successfully developed a set of core data elements to support the study of BPH surgical therapies by gathering an expert panel on BPH and using the Delphi method. These data elements influence provider decisions about treatment and include important outcomes related to efficacy and safety.
PURPOSE: To create a prospective, multicenter coordinated registry network (CRN) of robust "real world" data for benign prostatic hyperplasia (BPH) that links surgical practices to objective and subjective outcomes of patients who undergo surgery for the improvement in lower urinary tract symptoms (LUTS) secondary to BPH. METHODS: We gathered a group of BPH experts from various institutions to identify the minimum core data elements needed to assess BPH procedures. To achieve consensus on the data elements, we used a Delphi method adaptation, in which a series of surveys were answered by the expert panel individually and anonymously. Survey results were collected and analyzed. Questions for the following round were based on response analysis from the prior survey. This process was repeated until consensus was achieved. RESULTS: Participation rates in the first and second rounds were 100% and 90%, respectively. The expert panel reached consensus on 148 data elements out of the 182 proposed, capturing patient medical and surgical history, procedure, discharge, short- and long-term follow-up, device factors, surgery, and surgeon factors. CONCLUSION: We have successfully developed a set of core data elements to support the study of BPH surgical therapies by gathering an expert panel on BPH and using the Delphi method. These data elements influence provider decisions about treatment and include important outcomes related to efficacy and safety.
Authors: Lori B Lerner; Kevin T McVary; Michael J Barry; Brooke R Bixler; Philipp Dahm; Anurag Kumar Das; Manhar C Gandhi; Steven A Kaplan; Tobias S Kohler; Leslie Martin; J Kellogg Parsons; Claus G Roehrborn; John T Stoffel; Charles Welliver; Timothy J Wilt Journal: J Urol Date: 2021-08-13 Impact factor: 7.600